9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025 Pfizer aims to submit regulatory filings in ...

Pfizer said Tuesday morning that final trial studies still show its experimental COVID-19 pill significantly reduced the risk of hospitalization or death linked to the virus by 89%. The company also ...

At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer has completed a Phase 1 trial titled “A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Dose ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, Astellas Pharma and Pfizer Inc. (NYSE:PFE) announced positive topline results ...

Pfizer (PFE) and Astellas Pharma (ALPMY) announced on Wednesday that their antibody drug conjugate Padcev, with Merck’s (MRK) anti-PD-1 therapy Keytruda, succeeded in a Phase 3 pivotal trial for ...